1-Boc-piperidine-3-carboxylic acid phenyl amide | 309747-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Boc-piperidine-3-carboxylic acid phenyl amide
• 英文别名: 1,1-dimethylethyl 3-[(phenylamino)carbonyl]-1-piperidinecarboxylate；tert-butyl 3-(phenylcarbamoyl)piperidine-1-carboxylate
• CAS: 309747-36-2
• 化学式: C₁₇H₂₄N₂O₃
• 分子量: 304.389
• InChiKey: SFONCSRRVMNMHT-UHFFFAOYSA-N

物化性质

• 沸点：
  477.1±38.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-Boc-piperidine-3-carboxylic acid phenyl amide 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-phenylpiperidinecarboxamide hydrochloride
  参考文献：
  名称：

  [EN] ARYL-PIPERIDINE DERIVATIVES
  [FR] DÉRIVÉS D'ARYL-PIPÉRIDINE

  摘要：

  一种化学式I的芳基哌啶衍生物，其中R3、X、Cz和Cy的含义如描述中所指定，用作T细胞的抑制剂。

  公开号：

  WO2018170078A1
• 作为产物：
  描述：

  1-BOC-哌啶-3-羧酸 、 苯胺 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 以60%的产率得到1-Boc-piperidine-3-carboxylic acid phenyl amide
  参考文献：
  名称：

  Investigation of platelet aggregation inhibitory activity by phenyl amides and esters of piperidinecarboxylic acids

  摘要：

  A series of anilides and phenyl esters of piperidine-3-carboxylic acid (nipecotic acid) were synthesized and tested for the ability to inhibit aggregation of human platelet rich-plasma triggered by adenosine 5'-diphosphate (ADP) and adrenaline. As a rule, amides were about two times more active than the corresponding esters, and derivatives bearing substituents at the para position of the phenyl ring were significantly more active than the meta-substituted ones. Among the tested compounds, 4-hexyloxyanilide of nipecotic acid (18a) was found to be the most active one, its IC50 value being close to that of the most active bis-3-carbamoyl-piperidines reported in literature (ca. 40 muM) and aspirin (ca. 60 muM) in ADP- and adrenaline-induced aggregation, respectively. Compared with the isomeric 4-hexyloxyanilides of piperidine-2-carboxylic (pipecolinic) and piperidine-4-carboxylic (isonipecotic) acids, compound 18a showed higher activity, and a Hansch-type quantitative structure-activity relationship (QSAR) study highlighted lipophilicity and increase in electron density of the phenyl ring as the properties which mainly increase the antiplatelet activity (r(2) = 0.74, q(2) = 0.64). The interaction of nipecotoyl anilides with phosphatidylinositol, a major component of the inner layer of the platelet membranes, was investigated by means of flexible docking calculation methods to give an account of a key event underlying their biological action. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00599-0

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010120854A1

  公开（公告）日：2010-10-21

  The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代吲唑衍生物。具体而言，本发明涉及根据公式I的化合物：其中R1-R6和X在此定义。本发明的化合物是PDK1的抑制剂，可用于治疗由组成性激活的ACG激酶（如癌症，特别是白血病、乳腺癌、结肠癌和肺癌）引起的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。
• Heterocyclic analgesic compounds and methods of use thereof
  申请人：——

  公开号：US20020016337A1

  公开（公告）日：2002-02-07

  One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

  本发明的一个方面涉及新颖的杂环化合物。本发明的第二个方面涉及将这些新颖的杂环化合物作为各种细胞受体的配体，包括阿片受体、其他G蛋白偶联受体和离子通道。本发明的另一个方面涉及将这些新颖的杂环化合物用作镇痛剂。
• Antipsychotic sulfonamide-heterocycles, and methods of use thereof
  申请人：——

  公开号：US20020065265A1

  公开（公告）日：2002-05-30

  One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.

  本发明的一个方面涉及包含磺酰胺基团的杂环化合物。本发明的第二个方面涉及使用包含磺酰胺基团的杂环化合物来治疗至少部分由一个或多个GPCRs或配体门控离子通道的异常活动引起的疾病、痛苦或疾患。本发明的另一个方面涉及合成包含磺酰胺基团的杂环化合物的组合库，以及筛选这些库以寻找生物活性，例如在精神病动物模型中。
• 3-Substituted-4-pyrimidone derivatives
  申请人：Uehara Fumiaki

  公开号：US20050090490A1

  公开（公告）日：2005-04-28

  a pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1: wherein R 1 represents a C 1 -C 12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II): wherein R 2 and R 3 independently represent a hydrogen atom or a C 1 -C 8 alkyl group; R 4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 heteno atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

  一种以公式（I）表示的吡啶酮衍生物或其盐，或其溶剂或水合物，具有对tau蛋白激酶1的抑制活性：其中R1代表可以被取代的C1-C12烷基；R代表例如以下公式（II）所表示的基团：其中R2和R3独立地表示氢原子或C1-C8烷基；R4表示可以被取代的苯环，可以被取代的萘环，可以被取代的茚环，可以被取代的四氢萘环，或者是选择自氧原子、硫原子和氮原子组成的1至4个杂原子的可选取代杂环，总共具有5到10个构成环的原子。
• 3-substituted-4-pyrimidone derivatives
  申请人：Mitsubishi Pharma Corporation

  公开号：US07427615B2

  公开（公告）日：2008-09-23

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1: wherein R1 represents a C1-C12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II): wherein R2 and R3 independently represent a hydrogen atom or a C1-C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

  一种由公式（I）表示的吡啶酮衍生物或其盐、溶剂或水合物，具有对tau蛋白激酶1的抑制活性：其中R1代表可以被取代的C1-C12烷基；R代表例如以下公式（II）所表示的基团：其中R2和R3独立地表示氢原子或C1-C8烷基；R4表示可以被取代的苯环、可以被取代的萘环、可以被取代的茚环、可以被取代的四氢萘环，或者是具有1到4个杂原子（选自氧原子、硫原子和氮原子）的可选取代杂环，并且总共具有5到10个构成环的原子。